

Jan Moritz Middeke

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8736704/publications.pdf>

Version: 2024-02-01

31
papers

802
citations

840776

11
h-index

677142

22
g-index

32
all docs

32
docs citations

32
times ranked

1035
citing authors

#	ARTICLE	IF	CITATIONS
1	Deep learning detects acute myeloid leukemia and predicts NPM1 mutation status from bone marrow smears. <i>Leukemia</i> , 2022, 36, 111-118.	7.2	31
2	Differential impact of IDH1/IDH2 mutational subclasses on outcome in adult AML: results from a large multicenter study. <i>Blood Advances</i> , 2022, 6, 1394-1405.	5.2	17
3	Macroscopic, histologic, and clinical assessment of acute graft-versus-host disease of the upper gastrointestinal tract within 6 weeks after allogeneic hematopoietic cell transplantation. <i>Experimental Hematology</i> , 2022, 108, 36-45.	0.4	2
4	Deep learning identifies Acute Promyelocytic Leukemia in bone marrow smears. <i>BMC Cancer</i> , 2022, 22, 201.	2.6	14
5	Deep sequencing in CD34+ cells from peripheral blood enables sensitive detection of measurable residual disease in AML. <i>Blood Advances</i> , 2022, 6, 3294-3303.	5.2	11
6	Allogeneic hematopoietic cell transplantation for patients with TP53 mutant or deleted chronic lymphocytic leukemia: Results of a prospective observational study. <i>Bone Marrow Transplantation</i> , 2021, 56, 692-695.	2.4	3
7	Proof of concept for a rapidly switchable universal CAR-T platform with UniCAR-T-CD123 in relapsed/refractory AML. <i>Blood</i> , 2021, 137, 3145-3148.	1.4	70
8	Ruxolitinib for Glucocorticoid-Refractory Chronic Graft-versus-Host Disease. <i>New England Journal of Medicine</i> , 2021, 385, 228-238.	27.0	209
9	Tafasitamab combined with idelalisib or venetoclax in patients with CLL previously treated with a BTK inhibitor. <i>Leukemia and Lymphoma</i> , 2021, 62, 3440-3451.	1.3	6
10	Real-world experience of CPX-351 as first-line treatment for patients with acute myeloid leukemia. <i>Blood Cancer Journal</i> , 2021, 11, 164.	6.2	29
11	Long-Term Mixed Chimerism After Ex Vivo/In Vivo T Cell-Depleted Allogeneic Hematopoietic Cell Transplantation in Patients With Myeloid Neoplasms. <i>Frontiers in Oncology</i> , 2021, 11, 776946.	2.8	1
12	Clostridium Difficile infections in patients with AML or MDS undergoing allogeneic hematopoietic stem cell transplantation identify high risk for adverse outcome. <i>Bone Marrow Transplantation</i> , 2020, 55, 367-375.	2.4	10
13	TP53 abnormalities correlate with immune infiltration and associate with response to flotetuzumab immunotherapy in AML. <i>Blood Advances</i> , 2020, 4, 5011-5024.	5.2	85
14	Application of machine learning in the management of acute myeloid leukemia: current practice and future prospects. <i>Blood Advances</i> , 2020, 4, 6077-6085.	5.2	40
15	The prevalence of extramedullary acute myeloid leukemia detected by ¹⁸ F-FDG-PET/CT: final results from the prospective PETAML trial. <i>Haematologica</i> , 2020, 105, 1552-1558.	3.5	31
16	Engrafting human regulatory T cells with a flexible modular chimeric antigen receptor technology. <i>Journal of Autoimmunity</i> , 2018, 90, 116-131.	6.5	64
17	Pilot Study on Mass Spectrometry-Based Analysis of the Proteome of CD34+CD123+ Progenitor Cells for the Identification of Potential Targets for Immunotherapy in Acute Myeloid Leukemia. <i>Proteomes</i> , 2018, 6, 11.	3.5	10
18	Allogeneic stem cell transplantation for the treatment of refractory scleromyxedema. <i>Translational Research</i> , 2015, 165, 321-324.	5.0	13

#	ARTICLE	IF	CITATIONS
19	Adoptive transfer of allogeneic regulatory T cells into patients with chronic graft-versus-host disease. <i>Cytotherapy</i> , 2015, 17, 473-486.	0.7	149
20	Use of rasburicase in a pregnant woman with acute lymphoblastic leukaemia and imminent tumour lysis syndrome. <i>Annals of Hematology</i> , 2014, 93, 531-532.	1.8	5
21	Analysis of Molecular Predictors of Response to 5-Azacitine Treatment in AML and MDS Patients Preemptively Treated for Molecular Relapse of Disease. <i>Blood</i> , 2014, 124, 2384-2384.	1.4	0
22	Karyotypic Complexity In Acute Myeloid Leukemia In The Context Of Adverse Prognosis. <i>Blood</i> , 2013, 122, 489-489.	1.4	1
23	Outcome Of Patients With Abnl(17p) Acute Myeloid Leukemia After Allogeneic Hematopoietic Stem Cell Transplantation. <i>Blood</i> , 2013, 122, 303-303.	1.4	0
24	TP53 Mutations In Patients With High-Risk Acute Myeloid Leukemia Treated With Allogeneic Hematopoietic Stem Cell Transplantation. <i>Blood</i> , 2013, 122, 711-711.	1.4	0
25	Influence Of Steroid Exposure On CMV Specific T Cells Following Allogeneic Stem Cell Transplantation. <i>Blood</i> , 2013, 122, 5488-5488.	1.4	0
26	Clofarabine Salvage Therapy Prior To Allogeneic Hematopoietic Stem Cell Transplantation In Patients With Relapsed Or Refractory AML – Results Of The Bridge Trial –. <i>Blood</i> , 2013, 122, 304-304.	1.4	0
27	Reconstitution of IL-17-Producing T Helper Cells After Allogeneic Hematopoietic Cell Transplantation. <i>Blood</i> , 2012, 120, 4167-4167.	1.4	0
28	Systemic Iron Overload in Patients Undergoing Allogeneic Stem Cell Transplantation – a Magnetic Resonance Imaging Based Study in 81 AML and MDS Patients. <i>Blood</i> , 2011, 118, 489-489.	1.4	1
29	Comparing the Value of Serum Ferritin, Transfusion History and Magnetic Resonance Imaging for the Prediction of Iron Overload In MDS and AML Patients Undergoing Allogeneic Stem Cell Transplantation.. <i>Blood</i> , 2010, 116, 3493-3493.	1.4	0
30	Appearance of Mature 6-Sulfo LacNAc+ Dendritic Cells In Early and Late Engraftment After Allogeneic Stem Cell Transplantation.. <i>Blood</i> , 2010, 116, 3720-3720.	1.4	0
31	Monosomal Karyotype Predicts Survival In Patients with High Risk AML Undergoing Allogeneic Stem Cell Transplantation. <i>Blood</i> , 2010, 116, 2748-2748.	1.4	0